Compare HFWA & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | PRCT |
|---|---|---|
| Founded | 1927 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1997 | 2021 |
| Metric | HFWA | PRCT |
|---|---|---|
| Price | $27.18 | $18.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 15 |
| Target Price | ★ $32.40 | $22.42 |
| AVG Volume (30 Days) | 383.7K | ★ 1.3M |
| Earning Date | 10-22-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 58.06 | 1.71 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | $36.38 | $28.36 |
| Revenue Next Year | $7.77 | $20.55 |
| P/E Ratio | $30.63 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $21.32 | $16.67 |
| 52 Week High | $31.25 | $38.11 |
| Indicator | HFWA | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 45.96 |
| Support Level | $26.89 | $16.84 |
| Resistance Level | $28.13 | $22.88 |
| Average True Range (ATR) | 0.51 | 0.86 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 12.32 | 59.55 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.